Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by drongodragonon Apr 16, 2020 9:21am
128 Views
Post# 30915600

RE:RE:No more meat on the bone ...

RE:RE:No more meat on the bone ...If investors thought a 30-day single animal study for an intravenous drip was a curve ball, they’d be wrong, it’s the reverse! It should have been, Wow, is that at all? This is an addition to taking ifenprodil orally, which is going to happen with the South Korean trials.
 
No vaccine expert worth their salt will tell you a vaccine will be safe and ready for use in six months. Eighteen months is your best-case scenario, with nothing going wrong.  They haven’t found a vaccine for SARS after 17 years of trying. 
 
Treatment of the worst effects of Covid-19 is key to making people feel safe and getting back to work. Governments know this will be in the population for a long time as flattening the curve to protect the healthcare system prolongs the outbreak as it reduces the possibility of herd immunity. They need treatments.
Bullboard Posts